Research Library

Clinical study breakdowns and interactive data visualizations covering the mechanisms behind the ingredients we formulate with.

All research library

  • The NAD+ Precursor Trials That Found Nothing, and What They Still Tell Us — The controlled human trials of NMN, NR and urolithin A that missed their main outcome, set out with dose, size, duration and limits. Blood NAD+ rises reliably. Cognition, strength, insulin sensitivity and blood pressure mostly did not move in trials this short. The largest trial, a 52-week study of nicotinamide riboside in early Parkinson's disease, favored placebo. This is a Mt. Angel Vitamins company white paper. It is not a journal article and has not been through journal peer review.
  • The Synergistic NAD⁺ Stack: Interactive Data Visualizations — Interactive data visualizations comparing NAD⁺ bioavailability across monotherapy vs. the synergistic stack protocol. Charts cover 90-day NAD⁺ retention, telomere trajectory modeling, pathway bottleneck analysis, and the five-ingredient ecosystem approach.
  • Mitochondrial Quality Control and the Clinical Application of Urolithin A — A comprehensive clinical analysis of Urolithin A, a postbiotic metabolite that activates mitophagy through the PINK1/Parkin signaling pathway. Covers biosynthesis via the gut microbiome, human clinical trial data for muscle endurance and immune function, metabolic and neuroprotective research, pharmacokinetics, and safety.
  • Rauwolfia Serpentina & Reserpine: Pharmacological Mechanisms, Clinical Efficacy, and Modern Cardiovascular Applications — A comprehensive research report on Indian Snake Root (Rauwolfia serpentina) extract standardized for reserpine content, analyzing its VMAT-2 inhibition mechanism and modern clinical efficacy in refractory hypertension management.
  • Can Diet Raise NAD+? Tryptophan, Niacin and the De Novo Pathway — The question is whether eating more tryptophan or niacin raises NAD+ in human blood or tissue. The human studies so far measured urinary niacin breakdown products in small controlled diets. None measured blood NAD+ after food niacin or tryptophan. Nicotinamide riboside raised whole-blood NAD+ in several human trials, but no trial compares it with food. This is a Mt. Angel Vitamins company white paper, not a peer-reviewed article.
  • AmealPeptide® Hydrolyzed Casein: Pharmacological Mechanisms, Clinical Efficacy, and Therapeutic Applications — A comprehensive analysis of AmealPeptide® (VPP and IPP lactotripeptides), milk-derived bioactive peptides clinically proven to reduce blood pressure through natural ACE inhibition. Covering pharmacokinetics, multi-targeted mechanisms of action, landmark clinical trials, and emerging applications in sports nutrition and cognitive health.
  • Magnesium Amino Acid Chelate 40% Granular: An Exhaustive Clinical and Pharmacokinetic Analysis — A research-grade analysis of Magnesium Amino Acid Chelate 40% Granular — the buffered chelate behind Mt. Angel Vitamins' Good Magnesium — covering chemistry, bioavailability, absorption pathways, and manufacturing advantages versus pure bisglycinate, citrate, and oxide.
  • Urolithin A Dosage: What the Human Trials Tested — A company white paper from Mt. Angel Vitamins, not a peer-reviewed article. The published human urolithin A trials used 500 mg or 1,000 mg a day for four weeks to four months. They measured safety, blood and muscle markers, endurance, and immune cells. The primary performance outcomes in the main muscle trials were not significant. No trial we checked tested doses above 1,000 mg, so a dose plateau is unproven.
  • NOPARK: The 52-Week NR Trial in Early Parkinson's That Favored Placebo — NOPARK randomized 410 people with early Parkinson's disease to nicotinamide riboside (NR) or placebo for 52 weeks. NR did not improve the main rating score. The NR group got worse than placebo by an adjusted 2.72 points on that score, and nonmotor symptoms also worsened more on NR. This is a Mt. Angel Vitamins company white paper, not a journal article, and it has not been through journal peer review. It reads the trial's published abstract alongside the earlier NR studies in Parkinson's and the human NAD+ trials, and it says where the evidence stops.
  • Urolithin A and Immune Function: What the Human Trials Measured — This is a Mt. Angel Vitamins white paper, not a peer-reviewed article. It summarizes the human urolithin A immune studies. The one randomized trial that measured immune cells gave 50 healthy middle-aged adults 1,000 mg a day or placebo for four weeks. It moved some CD8 T cell measures and their metabolism. It did not measure infections, illness, or vaccine response, so it is not evidence of a clinical immune benefit.
  • NR and the Heart: What the Animal, Pharmacokinetic and Human Data Show — This is a Mt. Angel Vitamins company white paper, not a peer-reviewed article. It asks whether nicotinamide riboside (NR) helps the heart. Mouse heart studies are mostly positive. Human trials that measured heart, blood vessel or blood pressure outcomes are small and mostly null, and none tested heart events. NR reliably raises blood NAD in people. Searched PubMed on 22 October 2026.
  • Every Registered NMN, NR and Urolithin A Trial: A 2026 Registry Census — This is a company white paper from Mt. Angel Vitamins, not a peer-reviewed article. It counts the NMN, nicotinamide riboside (NR) and urolithin A trials registered on ClinicalTrials.gov as of 20 October 2026. We screened 376 records and kept 191 trials in scope. Most are small, and 92 have finished. Only 19 have posted results on the registry, and 31 completed trials have a linked paper. The census grades no outcome.
  • Who Pays for the NAD+ Precursor Trials? A Funding and Authorship Map — We mapped 69 human trials of NMN, NR and urolithin A and recorded who funded, supplied or wrote each one. Forty-nine of the 69 name a company as funder, supplier or author affiliation. In several papers, the conflict of interest statement says there are no competing interests while the same paper names a company as supplier or funder. This is a company white paper written by Mt. Angel Vitamins, a manufacturer in this category. It is not a peer-reviewed article.
  • Is NMN Legal in US Supplements? The FDA Timeline From 2022 to Today — This company white paper from Mt. Angel Vitamins, which is not peer-reviewed, traces NMN's US legal status through primary FDA documents. FDA excluded NMN from the dietary supplement definition in 2022 and 2023, then reversed that position in a letter dated September 29, 2025. The reversal is a legal reading. FDA does not approve supplements, NMN still requires a new dietary ingredient notification, and FDA's letter says nothing about whether NMN is safe or effective.
  • Can an NAD+ Precursor Change Biological Age? What Epigenetic Clocks Measure — Short answer: no trial we found establishes that an NAD+ precursor changes biological age. Epigenetic clocks estimate age from patterns in DNA methylation, and they remain research tools. One randomized pilot of nicotinamide riboside (NR) in 20 older adults with mild cognitive impairment reported a modest reduction in two clock estimates as an exploratory outcome. A 2026 systematic review counted that same result as not significant under its own rule. This is a company white paper from Mt. Angel Vitamins, not a peer-reviewed article. PubMed searches were run 20 October 2026.
  • NMN and NR Trials in Women: Who Was Enrolled, What Was Measured — This is a company white paper from Mt. Angel Vitamins, not a peer-reviewed article. It asks which NMN and NR trials enrolled women and what each one measured. On ClinicalTrials.gov, as of 22 October 2026, 12 oral trials are restricted to women, with 1,016 participants registered. Two have a paper we could verify: a 10-week NMN trial in 25 postmenopausal women, and a 7-day open-label NR trial in 40 women. No trial we read compared men and women directly, so a sex difference in NMN or NR effects has not been shown.
  • Urolithin A Clinical Data: An Interactive Visual Guide — Interactive visualizations of urolithin A clinical trial data including mitophagy mechanism, muscle endurance improvements, biomarker reductions, and ATP production scatter analysis.
  • Comprehensive Analysis of CDP-Choline Neuropharmacology: The Efficacy, Bioenergetics, and Manufacturing Superiority of Cognizin® Citicoline — An exhaustive, evidence-based analysis comparing Cognizin® patented fermentation-derived citicoline to generic synthetic citicoline across purity, pharmacokinetics, cerebral bioenergetics, clinical cognitive outcomes, and long-term stability.
  • Synergistic Modulation of the NAD⁺ Metabolome and Telomere Dynamics: NMN, NR, TMG, Resveratrol, and Zinc Co-Supplementation — A comprehensive analysis of why isolated NMN or NR supplementation hits biological bottlenecks, and how co-administering NMN, NR, TMG, resveratrol, and zinc creates a synergistic protocol that maximizes NAD⁺ bioavailability, prevents methylation drain, activates sirtuin longevity enzymes, and protects telomere architecture. Covers pharmacokinetics, the NNMT methylation sink, SIRT1/SIRT6 zinc-dependent mechanisms, resveratrol-driven tissue redistribution, and the hTERT telomerase activation pathway.
  • Celery Seed Extract (Apium graveolens): Phytochemistry, Pharmacological Mechanisms, and Clinical Efficacy Standardized to 8.8% Volatile Oils — A comprehensive clinical analysis of standardized celery seed extract (8.8% volatile oils) and its multi-pathway antihypertensive mechanisms including calcium channel blockade, endothelial NO-mediated vasodilation, and potassium-sparing diuresis. Meta-analytical evidence from 511 participants demonstrates significant reductions in systolic and diastolic blood pressure.
  • Neuropharmacological Efficacy of Synapsa (CDRI-08): A Comparative Analysis of Standardized Bacopa monnieri Extracts in Cognitive Enhancement — An exhaustive comparative analysis of the Synapsa (CDRI-08) standardized Bacopa monnieri extract versus generic formulations, covering phytochemical standardization, neurobiological mechanisms, clinical trial outcomes, and safety profile.